Glenmark Pays $25M to Resolve Alleged FCA Liability for Price-Fixing Pravastatin

September 11, 2024 |

Glenmark Pharmaceuticals has agreed to pay $25 million to resolve its alleged liability under the False Claims Act (FCA) for conspiring to fix the price of pravastatin, the Department of Justice (DOJ) announced.
Source: Drug Industry Daily